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Bloodspot screening has changed remarkably since 
the 1960s.  Up until 1998, additions to the panel were 
generally one disorder at a time.  Keeping up with 
changes were not difficult and there was plenty of 
preparation time available for training and education. 
With the introduction of tandem mass spectrometry, 
multiple disorders were added in a short time frame. 
In 2000 Iowa was screening for five disorders, by 2003 
the newborn screening panel had expanded to more 
than 40 disorders.  Needless to say, keeping up with 
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timing and other requirements has become increasing-
ly complicated.  Hopefully this will provide you with 
some insight and guidance for appropriate newborn 
screening and possible complications.
Myth 1:  No tests are accurate if done before 24 hours 
of age.
An initial screen for babies admitted to the NICU or 
special care nurseries upon admission is preferred tim-
ing, even if only a few hours/minutes old.  This way, at 
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Guidelines for Perinatal Services, 8th edition, 2008
The revised Guidelines for Perinatal Services has recently been published and distributed to hospitals.  For in-
dividual physicians, nurses or nursing units who wish to have a copy, an electronic version can be found on the 
Iowa Department of Public Health/Statewide Perinatal Care Program website. http://www.idph.state.ia.us/hpcdp/
statewide_perinatal_care.asp
Though there have been many updates to the 8th edition of the 2008 Guidelines, major additions include:
 1. Revised guidelines for the use of Pitocin.
 2. Inclusion of approved NICHD/AWHONN/ACOG nomenclature for electronic fetal monitoring.
 3. Revised guidelines for HIV testing and treatment during pregnancy.
 4. Guidelines for the screening of infants and women for perinatal illicit substance exposure.
Annual Iowa Conference on Perinatal Medicine
The 2008 Annual Iowa Conference on Perinatal Medicine was held April 9-10, 2008 at the West Des 
Moines Marriott Hotel.  The conference was an overwhelming success with the largest number of phy-
sician and nurse participants in many years.  Themes included The Current and Future Role of Genetics in 
Medicine, Maternal Depression, and Care for the Obese Parturient.  A link to view the 2008 brochure that in-
cludes a complete list of conference topics can be found at the Statewide Perinatal Care Program website. 
http://www.idph.state.ia.us/hpcdp/statewide_perinatal_care.asp
Mark your calendars!
The 2009 Annual Iowa Conference on Perinatal Medicine will be held on April 8-9, 2009 (Wednesday-Thursday) 
at the West Des Moines Marriott Hotel.  Please mark your calendars and plan to attend this important educational 
event designed to provide state-of-the-art information on obstetric and newborn care practices. 
NOTE:
 To be added to The Iowa Perinatal Letter mailing list contact Kathy Brogden via email at katherine-brogden@
uiowa.edu or call 319-356-2637.
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least one screen is assured to be done prior to any blood 
transfusions that may be needed.  All the enzyme dis-
orders are accurate, as is screening for hemoglobinopa-
thies.  So, if normal at admission, you can feel confident 
that biotinidase, galactosemia and hemoglobinopathy 
testing is normal.  Congenital adrenal hyperplasia and 
congenital hypothyroidism are not accurate because of 
collection prior to physiological hormone surge, and 
cutoffs are set for 24-72 hours of age, based on birth 
weight.  Cystic fibrosis testing may be falsely elevated 
in the first 24-48 hours of age, especially in premature 
and sick infants.1 Tandem mass spectrometry for the 
other disorders is probably not accurate since we are 
probably seeing mostly affects of placental clearance 
and not the baby’s physiology.
Myth 2:  Baby must be eating prior to NBS collection.
This is a frequently cited reason for waiting to screen 
babies later in life, about 72 hours of age or later.  The 
concern being that PKU or other disorders may be 
missed because of lack of protein intake.  With the old-
er modes of testing, testing was limited to milligrams 
per deciliter of serum.  With newer technologies uti-
lizing tandem mass spectrometry, sensitivities are im-
proved to micromoles per liter of serum.  So, sensitiv-
ity is much better and elevations of amino acids start 
at the time of birth, so 24 hours is plenty of time to see 
elevations.2 Some conditions like the fatty acid oxida-
tion defects may be easier to detect when the infant is a 
bit underfed as most are in the first 24-48 hours of life.
Myth 3:  More blood is better when applying it to the 
card.
The CDC has standardized the amount of blood that 
is in a punch from a blood spot and the calculations are 
based on this amount of blood.3 When blood is layered, 
the amount of serum in a punch is more than what our 
calculations are based upon.
Myth 4:  Baby looks fine so therefore it is unaffected.
The goal of newborn screening is to detect disorders 
prior to illness or complications.  Many of the disorders 
will not have signs or symptoms until after a week of 
life or later.  Some disorders will present with sudden 
onset of vomiting, hypoglycemia or electrolyte disor-
ders, but will not be occur until later in life.  Other dis-
orders may have a subtle onset with initial symptoms 
being missing developmental milestones or hypotonia. 
The point of this is that babies will be normal when 
testing is done and we should not rely on symptoms 
to determine the need for newborn screening.4 By the 
time symptoms appear, some damage has already oc-
curred.
Myth 5:  There are no family histories of disease; there-
fore, there is no need to screen for it since the disorders 
are so rare.
The majority of disorders covered by newborn 
screening are inherited in an autosomal recessive man-
ner.  The incidence of disease is then based on how 
often people are carriers for the disorder or if there is 
a history of consanguinity.  In the absence of consan-
guinity, unless there is an increased frequency in the 
population, there generally will not be a family history 
of the newborn-screened disorders.  However, if there 
is a high frequency of the gene mutation in the popula-
tions, such as sickle cell in those with African descent, 
then there is more likely to be a family history.  Need-
less to say, family history or lack thereof is not a good 
reason to not screen an infant.5
Myth 6:  Antibiotics interfere with newborn screening 
results.
This was a previous complication with bacterial 
inhibition assays since the reading was dependent 
upon growth of bacteria on an agar plate, so antibiotics 
could kill the bacteria and give a false negative read-
ing.  Then the next generation flurometric assays cross-
reacted with antibiotics causing false positive results.6 
However, this is not a problem inherent to tandem 
mass spectrometry. 
Myth 7:  If transfused prior to screening, none of the 
tests are accurate for 120 days.
Transfusion with red blood cells will give false nor-
mal results for galactosemia, hemoglobinopathy and 
biotinidase enzyme assays.  Transfusion of fresh frozen 
plasma or other plasma products will give false normal 
results for biotinidase enzyme assay.  Otherwise, in the 
absence of complete or partial exchange transfusion, 
the tandem mass spectrometry tests, cystic fibrosis test, 
and endocrinopathies will be accurate if collected ap-
propriately in the correct time frame.7
Myth 8:  For sick and premature infants, once you have 
a normal thyroid or CAH screen, then you know they 
are not affected.
False-negative results may be observed in preterm 
infants whose mothers were treated with steroids (to 
mature fetal lungs) and in neonates receiving dexam-
ethasone for management of unrelated problems.8  The 
hypothalamic-pituitary axis is immature in premature 
infants and thus thyroid levels may appear normal ini-
tially but require rechecks periodically to insure that 
infants will not eventually need thyroid replacement.9
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Myth 9:  It doesn’t make a difference if the baby is 
screened at 24 hours or 72 hours since Iowa Adminis-
trative Rules say screening can be done up to five days 
of age.
Prior to tandem mass spectrometry, the disorders 
screened on the heelstick panel all had a window of 
asymptomatic time from three to five days and treat-
ment could be started at a week without significant 
problems.  Now, with the addition of fatty acid oxida-
tion defects, urea cycle disorders and organic acidurias, 
onset of symptoms can be faster with more signficant 
complications, as early as in the first 72 hours of life.10 
Thus, screening at 24 hours of age will allow for detec-
tion hopefully before metabolic decompensation, and 
allowing for early treratment with good outcomes.  In 
Iowa with the use of the courier system and same day 
delivery, we can have results back to physicians within 
24 hours, which will allow us to detect and start treat-
ment much earlier.11
Myth 10: Thyroid screening on newborn screening is 
sensitive for all forms of congenital hypothyroidism.
In Iowa we only screen for TSH on the bloodspot. 
Thus, while the test is more specific for the majority 
of congenital forms of hypthyroidism, with fewer false 
positive results, some rare forms of hypothalamic- 
pituitary hypothyroidism may be missed.12
Myth 11:  The newborn screen blood spot is only valid 
if done from a heelstick.
There are some differences in serum levels for the 
analytes on newborn screen if collected from heelstick 
vs. venous/arterial line, but the differences are un-
likely to cause false negatives or false positive results. 
Heelstick is preferred, but sick and premature infants 
often have mutliple other factors and allowances can 
be made.  If the line is cleared appropriately with 2- 
2.5mL of blood prior to collection, it should be a valid 
specimen.  For further clarification, please see citation 
#3.  However, umbilical cord blood is NEVER appro-
priate for the newborn screening bloodspot.
Myth 12:  Infant has condition incompatible with life; 
therefore, no need to perform newborn screening.
The Iowa Administrative Rules specify that all in-
fants born must have a newborn screen. The rules also 
specify that even infants with a condition incompatible 
with life need a newborn screen.  The reason for this 
is more for future pregnancies and recurrence risk.  In 
particular, a fetus with nonimmune hydrops may have 
a particularly severe hemoglobinopathy that would not 
be detected otherwise.  Other instances are congenital 
malformations that may be completely unrelated, such 
as anencephaly but also has classic galactosemia.  In 
this case, while the recurrence for the anencephaly is 
about 2 percent, the recurrence risk for galactosemia is 
25 percent.  So, getting a screen is important; however, 
timing may be a bit more problematic, but it should 
still be collected as close to 24 hours as possible.  The 
specimen could even be from cardiac blood specimen.
Conclusion
Hopefully this will clarify some of the myths and 
misunderstandings about newborn screening.  As not-
ed above, there are several issues related to sick and 
premature infants that make getting an accurate speci-
men difficult.  Currently the Clinical and Laboratory 
Standards Institute (CLSI) is compiling a recommen-
dation related specifically to these infants.  The recom-
mendations will likely include several collection times, 
depending on specific reasons related to the condition 
of the infant and medical interventions.  These time 
recommendations will probably be as outlined below:
1. Upon admission to the NICU or special care 
nursery to avoid complications related to trans-
fusions
2. At 48-72 hours of age for the illnesses that 
require more rapid intervention 
3. At 28 days of age or discharge for late elevations 
related to CH and CAH as well as some compli-
cations related to hyperalimentation
For further direction and information there are 
many good online resources.   Below are two that can 
be good starting points and that have contact numbers 
and information for practitioners and the public. 
http://www.idph.state.ia.us/genetics/manual_toc.
asp  
- This is the Iowa Department of Public Health prac-
titioner’s manual which will include Iowa specific 
testing rules.
http://genes-r-us.uthscsa.edu/
-National Newborn Screening and Genetics Re-
source Center has information on all of the state 
programs and is the most up-to-date resource cur-
rently available.
 —Sara Copeland, MD 
 Clinical Assistant Professor of Pediatrics
 Division of Medical Genetics
 University of Iowa Children’s Hospital
 Medical Director of Newborn Screening for Iowa
 319-384-9601 Ph
 sara-copeland@uiowa.edu
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Though there have been many updates to the 8th edition of the 2008 Guidelines, major additions include:
 1. Revised guidelines for the use of Pitocin.
 2. Inclusion of approved NICHD/AWHONN/ACOG nomenclature for electronic fetal monitoring.
 3. Revised guidelines for HIV testing and treatment during pregnancy.
 4. Guidelines for the screening of infants and women for perinatal illicit substance exposure.
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